The schedule is tentative and subject to change.

Thursday, June 20
Room	HANRA A	HANRA B	HANRA C	SHILLA A	BAEKJE B	BAEKJE C	GOGURYEO	BAEKDU
FLOOR	3F				4F		5F
09:00-10:40	ES-1 [KOR]	ES-2 [KOR]	ES-3 [KOR]	YIS-1 [KOR]				Poster Presentation 1 (09:00-17:00)
	Clinical oncology for basic scientists	Recent advances in understanding and treating advanced GI cancer	Optimal combination of radiation therapy and immune checkpoint blockades	Korean Young Investigator Symposium
10:40-11:00	Coffee Break
11:00-11:30	Plenary Lecture 1 [ENG] - Prof. Sanghyuk Lee Integrative cancer genomics for precision medicine in lung cancer
11:30-12:20	Plenary Lecture 2 [ENG] - Dr. Walter J. Curran NRG Oncology, an international US NCI-supported cancer research group
12:20-13:20	LS-1 [ENG] – SANOFI GENZYME	LS-2 [ENG] – Servier	LS-3 [ENG] – AstraZeneca	LS-4 [ENG] – Pfizer
	Individualized treatment decision for optimal sequence in mCRC, with aflibercept	Liposomal irinotecan, new hope for the treatment of metastatic pancreatic cancer	Cutting-edge front-line treatment for advanced non-small cell lung cancer	Therapeutic strategy for maximizing overall survival for ALK/ROS1+ NSCLC
13:20-15:00	SP-01 [ENG]	SP-02 [ENG]	SP-03 [ENG]	SP-04 [ENG]	SP-05 [KOR]	SP-06 [ENG]	MC-1 [ENG]
	Conquering stomach cancer, the major cancer killer in Korea and Japan *KCA-JCA Joint Symposium	Tissue agnostic drug development	Updates on head and neck-thyroid oncology *KCA-CSCO Joint Symposium	Immunotherapy for rare cancer	Strategic plans of improving multicenter clinical trials	Vascular regulation of cancer progression *KCA-KVBM Joint Symposium	Recent updates in the development of immune-therapy for cancer treatment
15:00-15:20	Coffee Break
15:20-17:00	SP-07 [ENG]	SP-08 [ENG]	SP-09 [ENG]	SP-10 [ENG]	SP-11 [KOR]	IS-1 [ENG]	MC-2 [ENG]
	Current status of precision medicine in colorectal cancer *KCA-JSCO Joint Symposium	Advanced and innovative clinical research	Recent precision medicine in gynecologic and breast cancer *KCA-KSGO Joint Symposium	Omics for innovative clinical cancer research *KCA-KOGO Joint Symposium	Exchange and cooperation of oncology between South and North Korea	Precision medicine in head and neck and lung cancer	GC academy- Special talk for antiangiogenic agents in mGC treatment
17:00-18:00	OP-1 [KOR]	IS-3 [ENG]	OP-2 [KOR]		OP-3 [KOR]
	Omics and digital applications in cancer	Epigenetics, DNA, RNA in cancer	Issues in women cancers		Implements from novel observations

Language: [EN] Sessions in English, [KO] Sessions in Korean

SP-01	Joint Symposium of KCA & Japanese Cancer Association(JCA)
SP-03	Joint Symposium of KCA & Chinese Society of Clinical Oncology(CSCO)
SP-06	Joint Symposium of KCA & Korean Society for Vascular Biology and Medicine(KVBM)
SP-07	Joint Symposium of KCA & Japan Society of Clinical Oncology(JSCO)
SP-09	Joint Symposium of KCA & Korean Society of Gynecologic Oncology(KSGO)
SP-10	Joint Symposium of KCA & Korea Genome Organization(KOGO)

ES Educational Session	YIS Young Investigator Symposium	SP Symposium
MC Master Class	LS Luncheon Symposium	IS International Session (Oral)
OP Oral Presentation

Friday, June 21
Room	HANRA A	HANRA B	HANRA C	SHILLA A	BAEKJE B	BAEKJE C	GOGURYEO	BAEKDU
FLOOR	3F				4F		5F
09:00-10:00	Outstanding Abstract Session [ENG]		YIS-2 [KOR]		OP-4 [KOR]	IS-4 [ENG]		Poster Presentation 2 (09:00-17:00)
			Overseas Young Investigator Symposium		Translational research in H&N and lung cancer	Biomarkers and models in cancer immunotherapy
10:00-10:20	Coffee Break
10:20-10:50	Plenary Lecture 3 [ENG] - Dr. Yeul Hong Kim The complex path to cancer precision medicine
10:50-11:40	Plenary Lecture 4 [ENG] - Dr. Thomas Gajewski Tumor and host factors regulating anti-tumor immunity and immunotherapy efficacy
11:50-12:50	LS-5 [ENG] – MSD		LS-6 [ENG] – Roche	LS-7 [ENG] – Lilly
	The evolution from “Standard-of-Care” to “Standard-of-Survival”: Unfolding the quantum leap in mNSCLC		The evolving power of immunotherapy: Atezolizumab in advanced lung cancer	An optimal post-progression treatment option to improve advanced gastric cancer patient outcomes: Clinical experiences with ramucirumab
12:50-13:30	KCA General Assembly
13:40-15:20	SP-12 [ENG]	SP-13 [ENG]	SP-14 [KOR]	SP-15 [ENG]	IS-5 [ENG]	IS-6 [ENG]	MC-3 [ENG]
	Basic immunology: (Treatment-resistant) Tumor microenviron-ment	Immune targeted biomarkers in therapeutic decision making *KCA-KSP Joint Symposium	Promising anti-cancer drug pipeline in pre-clinical and clinical stages in Korea	Tumor micro-environment of solid cancer	Translational research in women cancers	Special populations in cancer prevention	How to generate and utilize RWE (real-world evidence) in oncology
15:20-15:40	Coffee Break
15:40-17:20	SP-16 [ENG]	SP-17 [KOR]	SP-18 [ENG]	SP-19 [KOR]	IS-7 [ENG]	IS-8 [ENG]
	Overcoming the current resistance to immune checkpoint inhibitors in cancer treatment *KCA-SITC Joint Symposium	Microbiology and microbiome in cancer *KCA-KSLM Joint Symposium	Current practice and dilemma in oligometastatic disease of lung cancer	암관련학회협의체 심포지엄	Translational research in GI cancers	New methods in tumor biology
17:30-18:30	Closing Reception @ GOGURYEO

Language: [EN] Sessions in English, [KO] Sessions in Korean

SP-13	Joint Symposium of KCA & The Korean Society of Pathologists(KSP)
SP-16	Joint Symposium of KCA & Society for Immunotherapy of Cancer(SITC)
SP-17	Joint Symposium of KCA & Korean Society for Laboratory Medicine(KSLM)

ES Educational Session	YIS Young Investigator Symposium	SP Symposium
MC Master Class	LS Luncheon Symposium	IS International Session (Oral)
OP Oral Presentation